0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.17.174.94. Please contact the publisher to request reinstatement.
The Cutting Edge |

Successful Treatment of Epidermolysis Bullosa Pruriginosa With Topical Tacrolimus FREE

Jeremy P. Banky, MBBS; Adam T. Sheridan, FACD; Emma L. Storer, MBBS; Gillian Marshman, FACD
[+] Author Affiliations

Section Editor: George J. Hruza, MD
Assistant Section Editor: Michael P. Heffernan, MD
Assistant Section Editor: Elaine Siegfried, MD

More Author Information
Arch Dermatol. 2004;140(7):794-796. doi:10.1001/archderm.140.7.794.
Text Size: A A A
Published online

A 53-year-old white woman with epidermolysis bullosa (EB) pruriginosa presented to the dermatology clinic seeking therapy for localized severe andintractable pruritus. At the age of 4 years the patient developed an extremely pruritic bullous eruption characterized by fragile blisters, erosions, andexcoriations affecting sites subject to friction and pressure, particularly the ankles and knees. By the age of 21 years, the patient had large lichenifiedplaques, areas of linear violaceous scarring, multiple milia, and erosions over much of the extensor surfaces of the legs, forearms, buttocks, and dorsumof the feet (Figure 1A and B). All of her 20 nails were grossly dystrophic (Figure 1C). Mucous membranes were normal. There was a family historyof EB pruriginosa, as the patient's younger brother and daughter were similarly affected.

Place holder to copy figure label and caption
Figure 1.

Lichenified plaques, linear violaceous scarring, erosions, and milia are affecting the extensor surfaces of the legs(A), forearm (B), and feet (C). All toenails were dystrophic.

Graphic Jump Location

Electron microscopical features supported the diagnosis of EB pruriginosa: separation at the sublamina densa level of the dermoepidermal junction andabnormal anchoring fibrils that were scanty, disorganized, and not fully developed (Figure 2). Blood cell count andserum biochemistry findings were normal. Serum levels of thyroid hormones, ferritin, and IgE were all within normal ranges.

Place holder to copy figure label and caption
Figure 2.

Electron microscopic appearances of lesional skin on the shin showing (1) keratinocytes, (2) lamina densa abovethe level of separation, (3) separation at the sublamina densa level of thedermoepidermal junction, and (4) upper dermis (original magnification ×76 000).

Graphic Jump Location

Throughout the course of the disease, intractable pruritus was the most prominent and severe feature, far outweighing the significant cosmetic disability.Continuous rubbing and scratching generated large areas of disease over the shins and forearms. The patient often presented with areas of frank bleedingresulting from deep excoriations. Treatments included inpatient and outpatient care with a combination of intensive emolliation, potent topical corticosteroids,sedating antihistamines, and behavioral therapy. These resulted in short-term control of the cutaneous manifestations, but not sustained improvement orcontrol of the pruritus. Thinning of the skin secondary to the ongoing use of potent topical steroids was also evident.

Epidermolysis bullosa pruriginosa is a rare condition of poorly understood pathogenesis. Therapeutic results are currently disappointing as targetedtreatments are yet to be defined. In our patient, intractable pruritus wasby far the most troublesome feature. A vicious cycle was established as theextreme itch precipitated paroxysms of scratching, resulting in new and persistent areas of disease. Our patient had been relatively unresponsive to topicalsteroids and long-term use had compounded the skin fragility by inducing significant cutaneous atrophy. The patient was reluctant to take any systemic medication.Our challenge was to find a safe and effective therapy that would target the pruritus without the side effects of topical corticosteroids.

Since systemic cyclosporine has been used in EB pruriginosa with some success,1 topical tacrolimus was consideredas an alternative therapeutic approach. Therapy was initiated with 0.03% tacrolimus ointment to the legs and forearms twice daily. Within 1 week of applying theointment, a significant decrease in the pruritus was reported, resulting in a marked reduction in scratching. Progression of the lichenified plaques,linear violaceous scars, milia, and erosions was arrested and in some areas the lichenified plaques were reduced (Figure3). The patient has used 0.03% tacrolimus ointment for 6 months without complication and remains under excellent symptomatic control.

Place holder to copy figure label and caption
Figure 3.

Six months after treatment the forearms demonstrate reduction in lichenification, with persistent backgroundmilia and scarring.

Graphic Jump Location

Epidermolysis bullosa pruriginosa is a form of dystrophic EB characterized by prurigolike or lichenified lesions associated with scarring.2 Itis usually confined to the shins and forearms.2 The ultrastructural hallmark is a sublamina densa split associated with an alterationin the number and structure of the anchoring fibrils at the dermal-epidermal junction.2 The onset of clinical features maybe evident in early childhood, as in our patient, but in some cases appears later, in the second and third decades of life.3

The mode of inheritance is variable. McGrath et al2 described 8 unrelated cases of EB pruriginosa, of which 5 were sporadic, 2 were autosomaldominant, and 1 was recessive. Mellerio et al3 described both dominant and recessive type VII collagen gene (COL7A1) mutations underlying the EB pruriginosa phenotype. Yu-Yun Lee etal4 and Jiang et al5 examined separate Chinese families with dominant EB pruriginosa who had different COL7A1 mutations. Our patient has a brother and a daughtersimilarly affected, and the mode of inheritance appears to be autosomal dominant.

The development of EB pruriginosa phenotype has yet to be defined.6 Molecular heterogeneity and compound heterozygosity in COL7A1 mutations have been demonstrated in patientswith EB pruriginosa.3 Other genetic and environmental factors are also likely to contribute to this specific phenotype, as mutationsin COL7A1 have been demonstrated in patients with both EB pruriginosa and dystrophic EB of nonpruriginous phenotype.3

Treatment is aimed at controlling pruritus and halting the progression of cutaneous lesions. Potent topical steroids and intralesional triamcinolonehave been reported to reduce the pruritus in some cases, but do not produce sustained improvement.2 Systemic therapy withhistamine1 antihistamines, corticosteroids, or etidronate had no sustained effect.2 Oral administration of cyclosporinehas been reported in 1 case as controlling the cutaneous lesions and decreasing the pruritus.1

The aim of treatment in our patient was to eliminate the pruritus, as her scratching was traumatizing the skin and contributing to disease progression.The pathogenesis of the pruritus is poorly understood. Raised serum levels of IgE have been noted in some patients with EB pruriginosa, although elevatedIgE levels do not specifically account for a pruriginosa phenotype.3

Tacrolimus is a macrolide immunosuppressant produced by the soil fungus Streptomyces tsukubaensis. Topical application of tacrolimus in treating atopic eczema710 iswell described. Cases of steroid-induced rosacea,11 pyoderma gangrenosum,12 lichen planus,13 andichthyosis linearis circumflexa14 have been successfully treated with topical tacrolimus.

Topical tacrolimus was considered in our patient because the literature suggests that it has an antipruritic action.1517 Theexact mode of this action is unclear. De Paulis et al16 showed that tacrolimus acted on skin mast cells challenged with anti-IgE antibodiesto inhibit histamine release in a concentration-dependent manner and impair de novo synthesis of prostaglandin D2. Eberlein-König et al17 demonstrated that tacrolimus diminished the enhancingeffect of interleukin-3 on anti-IgE-antibody–induced histamine release from basophils. The relevance of this phenomenon to EB pruriginosa is unclearbecause it is considered a mechanobullous disease.

Treatment with topical tacrolimus in our patient had minimal effect upon preexisting visible disease. The lack of a dramatic effect on establishedskin lesions was not unexpected, as EB pruriginosa is associated with an underlying COL7A1 mutation and tacrolimus does not affect collagen synthesis.18

We believe that topical tacrolimus has potential benefits over topical corticosteroids when treating EB pruriginosa. There are currently no reportsof systemic adverse effects after topical tacrolimus application.19 Although topical corticosteroids are generally well tolerated, they may cause systemic problems such as acne, hyperglycemia, growthretardation, and adrenal insufficiency when applied to large areas.20 Most importantly, tacrolimus, unlike topical steroids, does not cause cutaneous atrophy.18,21 Thesewere important considerations in our patient whose pathological cutaneous fragility was compounded by steroid-induced atrophy.

To the best of our knowledge, this is the first reported case of EB pruriginosa successfully treated with topical tacrolimus. By alleviating ourpatient's itch, disease progression was slowed and her quality of life was markedly improved. With its steroid-sparing effects and lack of documentedsystemic adverse reactions, we consider topical tacrolimus to be of significant benefit in treating EB pruriginosa.

Correspondence: Jeremy P. Banky, MBBS, Dermatology Registrar, Churchill Hospital, Oxford Radcliffe Hospitals, Headington, Oxford, OX37LJ England (jembanky@hotmail.com).

Accepted for publication September 23, 2003.

The authors have no relevant financial interest in this article.

Submissions

Clinicians, local and regional societies, residents, and fellows are invited to submit cases of challenges in management and therapeutics to thissection. Cases should follow the established pattern. Submit 4 double-spaced copies of the manuscript with right margins nonjustified and 4 sets of theillustrations. Photomicrographs and illustrations must be clear and submitted as positive color transparencies (35-mm slides) or black-and-white prints.Do not submit color prints unless accompanied by original transparencies. Material should be accompanied by the required copyright transfer statement,as noted in "Instructions for Authors." Material for this section should be submitted to George J. Hruza, MD, Laser and Dermatologic Surgery Center Inc,14377 Woodlake Dr, Suite 111, St Louis, MO 63017.

Yamasaki  HTada  JYoshioka  TArata  J Epidermolysis bullosa pruriginosa (McGrath) successfully controlled by oral cyclosporin Br J Dermatol. 1997;137308- 310
PubMed
McGrath  JASchofield  OMVEady  RAJ Epidermolysis bullosa pruriginosa: dystrophic epidermolysis bullosa with distinctive clinicopathological features Br J Dermatol. 1994;130617- 625
PubMed
Mellerio  JEAshton  GHSMohammedi  R  et al.  Allelic heterogeneity of dominant and recessive COL7A1 mutations underlying epidermolysis bullosa pruriginosa J Invest Dermatol. 1999;112984- 987
PubMed
Yu-Yun Lee  JPulkkinen  LLiu  HSChen  YFUitto  J Glycine-to-arginine substitution in the triple-helical domain of type VII collagen in a family with dominant dystrophic epidermolysis bullosa pruriginosa J Invest Dermatol. 1997;108947- 949
PubMed
Jiang  WBu  DYang  YZhu  X A novel splice site mutation in collagen type VII gene in a Chinese family with dominant dystrophic epidermolysis bullosa pruriginosa Acta Derm Venereol. 2002;82187- 191
PubMed
Horn  HMTidman  MJ The clinical spectrum of dystrophic epidermolysis bullosa Br J Dermatol. 2002;146267- 274
PubMed
Ruzicka  TBieber  TSchopf  E  et al.  A short-term trial of tacrolimus ointment for atopic dermatitis N Engl J Med. 1997;337816- 821
PubMed
Hanifin  JMLing  MRLangley  RBreneman  DRafal  Efor the Tacrolimus Ointment Study Group, Tacrolimus ointment for the treatment of atopic dermatitis in adult patients, I: efficacy J Am Acad Dermatol. 2001;44(suppl)S28- S38
PubMed
Reitamo  SWollenberg  ASchopf  E  et al.  Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis Arch Dermatol. 2000;136999- 1006
PubMed
Kang  SLucky  AWPariser  DLawrence  IHanifin  JMfor the Tacrolimus Ointment Study Group, Long-term safety and efficacy of tacrolimus ointment for the treatmentof atopic dermatitis in children J Am Acad Dermatol. 2001;44(suppl)S58- S64
PubMed
Goldman  D Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report J Am Acad Dermatol. 2001;44995- 998
PubMed
Richter-Hintz  DSchuppe  HCHomey  BLehmann  PRuzicka  T Topical tacrolimus (FK506) is effective in the treatment of pyoderma gangrenosum. [comment] J Am Acad Dermatol. 2000;42304- 305
PubMed
Lener  EVBrieva  JSchachter  MWest  LEWest  DP Successful treatment of erosive lichen planus with topical tacrolimus Arch Dermatol. 2001;137419- 422
PubMed
Suga  YTsuboi  RHashimoto  YYoshiike  TOgawa  H A case of ichthyosis linearis circumflexa successfully treated withtopical tacrolimus J Am Acad Dermatol. 2000;42520- 522
PubMed
Nakagawa  HEtoh  TIshibashi  Y  et al.  Tacrolimus ointment for atopic dermatitis [letter] Lancet. 1994;344883
PubMed
De Paulis  AStellato  CCirillo  RCiccarelli  AOriente  AMarone  G Anti-inflammatory effect of FK-506 on human skin mast cells J Invest Dermatol. 1992;99723- 728
PubMed
Eberlein-König  BRuzicka  TMichel  GPrzybilla  B Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation Arch Dermatol Res. 1997;289606- 608
PubMed
Reitamo  SRissanen  JRemitz  A  et al.  Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial J Invest Dermatol. 1998;111396- 398
PubMed
Skaehill  PA Tacrolimus in dermatologic disorders Ann Pharmacother. 2001;35582- 588
PubMed
Lee  NPArriola  ER Topical corticosteroids: back to basics West J Med. 1999;171351- 353
PubMed
Nasr  IS Topical tacrolimus in dermatology Clin Exp Dermatol. 2000;25250- 254
PubMed

Figures

Place holder to copy figure label and caption
Figure 1.

Lichenified plaques, linear violaceous scarring, erosions, and milia are affecting the extensor surfaces of the legs(A), forearm (B), and feet (C). All toenails were dystrophic.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Electron microscopic appearances of lesional skin on the shin showing (1) keratinocytes, (2) lamina densa abovethe level of separation, (3) separation at the sublamina densa level of thedermoepidermal junction, and (4) upper dermis (original magnification ×76 000).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Six months after treatment the forearms demonstrate reduction in lichenification, with persistent backgroundmilia and scarring.

Graphic Jump Location

Tables

References

Yamasaki  HTada  JYoshioka  TArata  J Epidermolysis bullosa pruriginosa (McGrath) successfully controlled by oral cyclosporin Br J Dermatol. 1997;137308- 310
PubMed
McGrath  JASchofield  OMVEady  RAJ Epidermolysis bullosa pruriginosa: dystrophic epidermolysis bullosa with distinctive clinicopathological features Br J Dermatol. 1994;130617- 625
PubMed
Mellerio  JEAshton  GHSMohammedi  R  et al.  Allelic heterogeneity of dominant and recessive COL7A1 mutations underlying epidermolysis bullosa pruriginosa J Invest Dermatol. 1999;112984- 987
PubMed
Yu-Yun Lee  JPulkkinen  LLiu  HSChen  YFUitto  J Glycine-to-arginine substitution in the triple-helical domain of type VII collagen in a family with dominant dystrophic epidermolysis bullosa pruriginosa J Invest Dermatol. 1997;108947- 949
PubMed
Jiang  WBu  DYang  YZhu  X A novel splice site mutation in collagen type VII gene in a Chinese family with dominant dystrophic epidermolysis bullosa pruriginosa Acta Derm Venereol. 2002;82187- 191
PubMed
Horn  HMTidman  MJ The clinical spectrum of dystrophic epidermolysis bullosa Br J Dermatol. 2002;146267- 274
PubMed
Ruzicka  TBieber  TSchopf  E  et al.  A short-term trial of tacrolimus ointment for atopic dermatitis N Engl J Med. 1997;337816- 821
PubMed
Hanifin  JMLing  MRLangley  RBreneman  DRafal  Efor the Tacrolimus Ointment Study Group, Tacrolimus ointment for the treatment of atopic dermatitis in adult patients, I: efficacy J Am Acad Dermatol. 2001;44(suppl)S28- S38
PubMed
Reitamo  SWollenberg  ASchopf  E  et al.  Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis Arch Dermatol. 2000;136999- 1006
PubMed
Kang  SLucky  AWPariser  DLawrence  IHanifin  JMfor the Tacrolimus Ointment Study Group, Long-term safety and efficacy of tacrolimus ointment for the treatmentof atopic dermatitis in children J Am Acad Dermatol. 2001;44(suppl)S58- S64
PubMed
Goldman  D Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report J Am Acad Dermatol. 2001;44995- 998
PubMed
Richter-Hintz  DSchuppe  HCHomey  BLehmann  PRuzicka  T Topical tacrolimus (FK506) is effective in the treatment of pyoderma gangrenosum. [comment] J Am Acad Dermatol. 2000;42304- 305
PubMed
Lener  EVBrieva  JSchachter  MWest  LEWest  DP Successful treatment of erosive lichen planus with topical tacrolimus Arch Dermatol. 2001;137419- 422
PubMed
Suga  YTsuboi  RHashimoto  YYoshiike  TOgawa  H A case of ichthyosis linearis circumflexa successfully treated withtopical tacrolimus J Am Acad Dermatol. 2000;42520- 522
PubMed
Nakagawa  HEtoh  TIshibashi  Y  et al.  Tacrolimus ointment for atopic dermatitis [letter] Lancet. 1994;344883
PubMed
De Paulis  AStellato  CCirillo  RCiccarelli  AOriente  AMarone  G Anti-inflammatory effect of FK-506 on human skin mast cells J Invest Dermatol. 1992;99723- 728
PubMed
Eberlein-König  BRuzicka  TMichel  GPrzybilla  B Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation Arch Dermatol Res. 1997;289606- 608
PubMed
Reitamo  SRissanen  JRemitz  A  et al.  Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial J Invest Dermatol. 1998;111396- 398
PubMed
Skaehill  PA Tacrolimus in dermatologic disorders Ann Pharmacother. 2001;35582- 588
PubMed
Lee  NPArriola  ER Topical corticosteroids: back to basics West J Med. 1999;171351- 353
PubMed
Nasr  IS Topical tacrolimus in dermatology Clin Exp Dermatol. 2000;25250- 254
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles